

INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES

Published by JK Welfare & Pharmascope Foundation

Journal Home Page: www.ijrps.com

Beneficial effects of long term caloric vestibular stimulation on changes in brain neurotransmitter dopamine and locomotor activity in Parkinson's Disease induced rats

Thanalakshmi J¹, Archana R^{*1}, Senthil Kumar S²

¹Department of Physiology, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai 602105, Tamilnadu, India

²Department of Research and Development, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai - 602105, Tamilnadu, India

*Corresponding Author

Name: Archana R Phone: +91-9840608149 Email: dr.rarchana@gmail.com

ISSN: 0975-7538

DOI: https://doi.org/10.26452/ijrps.v11iSPL2.2694

Production and Hosted by

IJRPS | www.ijrps.com

© 2020 | All rights reserved.

INTRODUCTION

Parkinson's Disease (PD) is a neurodegenerative disorder caused by progressive degeneration of dopaminergic neurons in pars compacta of the substantia nigra, causing subsequent loss of axonal terminals in the corpus striatum. It is known to affect the nigrostriatal dopaminergic pathway in Parkinson's Disease (PD) (Fearnley and Lees, 1991). This results in motor incoordination and reduced motor activity associated with rigidity and tremor. Parkinson's Disease is associated with pathological features like loss of dopaminergic neurons and the presence of neuronal protein aggregates known as Alpha-synuclein, subsequently leading to reduced dopamine secretions (Tieu, 2011). The molecular mechanism behind the genesis of PD is mitochondrial complex I inhibition and release of free radicals in circulation, leading to neuronal apoptosis (Narasimhan *et [al.](#page-4-0)*, 20[19\).](#page-4-0) The dopaminebased medications given for a long duration will exceed the normal concentration of dopamine available in the midbrain (Yabe *et al.*, 2014). The alternate t[reatment methods like d](#page-3-1)eep brain stimulations were not suitable for the older population as it fails to address motor incoordination (Sharma *et al.*, 2019). In th[is regard, new c](#page-4-1)onventional treatment methods are required to overcome the neurochemical changes in the brain of Parkinson's disease. Caloric Vestibular Stimulations ([CVS\) are](#page-3-2) [know](#page-3-2)n [to imp](#page-3-2)rove motor deficits in neurological disorders like Alzheimer's disease and Parkinson's Disease. (Suzuki *et al.*, 2001; Gopinath *et al.*, 2015). The CVS is a simple and non-invasive technique that triggers the vestibular nucleus through the afferent vestibular nerve. It subsequently leads to the activation of [contralateral](#page-4-2) c[ortica](#page-4-2)l [structures \(Suzu](#page-3-3)ki *[et al](#page-3-3).*, 2001). Previous studiesobserved that stimulation of the vestibular apparatus increases acetylcholine release from rat hippocampus during anxiety and depression. It is also known to enhanc[e memory by](#page-4-2) [activa](#page-4-2)ting through a cholinergic pathway of the hippocampus (Horii *et al.*, 1994; Sailesh *et al.*, 2014b). However, the literature evidence for the beneficial effect of CVS on the prevention of Parkinson's Disease induced by rotenone is undetermined. For that reason, the [present study w](#page-3-4)as conducted to find the efficacy of bilateral warm water CVS in protecting dopaminergic neuronal loss in rats of Parkinson's Disease induced by intraperitoneal injection of Rotenone.

MATERIALS AND METHODS

Experimental design

Thirty Wistar male albino rats weighing around 250 - 300g were grouped as follows with each group containing 6 animals.

Grp 1: Control animal with no intervention

Grp 2: PD (administrated rotenone 3mg/kg body weight/day i.p mixed with vehicle; 98% Olive oil and 2% DMSO for 21 days)

Grp 3: PD+CVS: PD induced and CVS gave for 45 days

Grp 4: PD R (PD induced for 21 days and left untreated to study for its recovery)

Grp 5: CVS (Only intervention has given)

All animals were kept under environmentally controlled conditions with food and water adlibitum. The Parkinson's Disease was induced in the animal by intraperitoneal injection of Rotenone at a dose of 3mg/kg body weight for 21 days. The Rotenone was administered after mixing with 98%DMSO and 2% olive oil as a vehicle (Cannon *et al.*, 2009). The present work was approved by the Institutional Animal Ethical Committee of Saveetha Medical College and Hospital [IEC no: SU/CLAR/RD/006/2018].

In order to avoid chan[ge in the results d](#page-3-6)ue to variations in accordance with circadian rhythms of Dopamine level, all the experiments involving estimation of Dopamine was done between 8 am to 10 am. After the intervention of vestibular stimulation for 45 days following induction of Parkinson's Disease, the animals were sacrificed by cervical disruption and brain were removed quickly for HPLC estimation of Dopamine.

Caloric Vestibular Stimulation (CVS) procedure

The rat middle ear was irrigated with warm water of 42*^o*C. Bilateral vestibular stimulation was done by irrigating each ear with 2.0ml of warm water administered at a flow rate of about 0.1 ml/sec using the syringe for 2 minutes (Sailesh *et al.*, 2014a).

Behavioral Parameter

Actophotometer was used to assess the locomotor activity of the animal, [which opera](#page-3-7)t[es base](#page-3-7)d on the emission of photoelectric cells which are connected in circuit with a counter. Based on the movement of an animal inside the closed square arena the count was recorded for 180 seconds (Tieu, 2011)

Standard Preparation of dopamine

The primary standard of dopamine hydrochloride was prepared by dissolving 1[0 mg of co](#page-4-0)mpounds with 10 ml methanol in a volumetric flask (1 mg/ml). From the above standard stock solution, series of dilutions viz., 0.125 *µ*g/ml, 0.500 μ g/ml,0.750 μ g/ml and 1 μ g/ml were prepared in the methanol and was used as 100 % target concentration.

Sample preparation

The dopamine in the corpus striatum of the rat brain was estimated as done by Wagner *et al.* (1982) The rats were sacrificed by cervical dislocation. The brain was rapidly removed by placing on an ice-cold plate and corpus striatum was dissected out. The corpus striatum was hom[ogenized with perch](#page-4-3)loric acid, followed by centrifugation. The homogenate was centrifuged in a refrigerated centrifuge (12000 rpm, 4*◦* c) for 2 minutes and the supernatant was collected. The collected supernatant was again centrifuged at (12000 rpm, 4*◦* c) for 20 minutes. The supernatant was filtered with a $0.22 \mu m$ membrane filter and 20μ of the sample was injected into the Rheodyne injector of the HPLC system.

Estimation of Dopamine (DA)

Determination of Dopamine hydrochloride (DA) was done using High-performance liquid chromatography with a PDA detector. The homogenate samples of rat striatum employing the direct UV range of the neurotransmitters are used. The method has been optimized and validated. The analytics were separated in 10 min on a reversed-phase column (C_{18}) with 0.5 % Acetic acid buffer & methanol (70:30) as the mobile phase; the flow rate was 1 ml/min. The UV measurements were carried out at 277 nm. The calibration curve for DA was linear up to about 1 g/ml, with a coefficient of determination (r^2) of 0.9995 with a lower limit of quantification of 0.118 g/ml. Since the procedure does not involve sample pre-purification or derivatisation, the recovery ranged from 97% to 102% and relative standard deviation (RSD) was better than 1.910 %; the use of the internal standard is not mandatory.

STATISTICAL ANALYSIS

All the experimental data were statistically analyzed by SPSS statistical software version 20. One way ANOVA followed by Tukey's HSD was done to compare the mean difference between the groups. P<0.05 was considered significant.

RESULTS AND DISCUSSION

The level of Dopamine expressed as mg/L in all the groups studied is summarized in (Figure 1). The results are expressed as mean*±*SD. Parkinson's Disease group (Figure 1) showed a significant decrease (p<0.05) in dopamine concentration (0.18*±*0.03) when compared to the control group (0.4[6](#page-2-0)*±*0.09) in the corpus striatum. The intervention group, i.e., PD+CVS 45 da[ys](#page-2-0) (0.24 ± 0.03) , showed significant improvement in (p<0.04) dopamine level when compared to the PD group. The PD R group has also shown a significant (0.20±0.03) decrease in the concentration of Dopamine, indicating that the rotenone has brought irreversible damage to the nigrostriatal neurons, whereas only CVS group (0.40*±*0.08) showed similar results as that of control.

The activity score results, as measured in the actophotometer on the 45 days, were found to be reduced in the PD group (83*±*27) when compared to the control group rats (302*±*26). Vestibular stimulation for 45 days ($p < 0.04$) has significantly increased the activity score (263*±*37), whereas the PD R, Figure 2 has shown a significant $(p<0.03)$

Figure 1: Dopamine concentration (mg/L) in the corpus striatum of control and study group

Figure 2: Activity score estimation by Actophotometer

decrease in activity score (92*±*23) (Figure 2).

The present study showed that CVS for the period of 45 days improves the dopamine level in the corpus striatum and motor activity in rotenone-induced PD rats. As anticipated, intraperitoneal [in](#page-2-1)jection of Rotenone has brought about significant changes in the behavioral parameters as these rats (PD group) exhibited a progressive decrease in motor activity when compared with the control group. A similar observation was done by von Wrangel *et al.* (2015), who has stated that Rotenone injection shows impairment in the rotarod and hanging wire test. These alterations in PD group are due to the degeneration of dopamin[ergic neurons](#page-4-4) [in the Substa](#page-4-4)ntia nigra pars compacta, as observed in the brain neuropathological changes (Alam and Schmidt, 2002). It is also characterized by loss of neuronal cells with decreased intensity of TH staining in the striatal regions. Reduction in dopamine levels in the striatum and oxidative str[ess causes](#page-3-8) [loss of motor c](#page-3-8)oordination in the Rotenone treated animal (Saravanan *et al.*, 2005). The Rotenone infusion brings about mitochondrial inhibition causing reduced production of ATP, which is necessary for movement and motor co-ordination (Sherer *et al.*, 2003). [The effect of galvanic v](#page-3-9)estibular stimulation

on discrete brain regions of neurotransmitter level, as well as improvement of axial motor function, has been reported earlier. (Samoudi *et al.*, 2012) found that galvanic vestibular stimulation (GVS) improved locomotor activity, measured by performance on a rotarod, and enhanced GABA release in the substantia nigra; however, [DA release in the st](#page-3-11)riatum was not significantly affected in Hemi parkinsonism of rats. In this study, dopamine neurotransmitter was reduced after inter peritoneal injection of rotenone and CVS has shown a normalizing effect on dopamine neurotransmitter of the corpus striatum. As a result, it was found to reduce neuronal degeneration. The study also confirms that the vestibular stimulation can trigger the vestibular nucleus in the midbrain and subsequently trigger the motor area of the cerebral cortex, thus bringing change in the neuronal firing via extra pyramidal connections down to the spinal cord. By acting via the vestibulospinal pathway, it is bringing alterations in the motor activity of the animals. However, Rotenone induced behavioral alterations are attenuated on intervention with Caloric vestibular stimulations. These improvements in behavioral changes by CVS are attributed to the prevention of degeneration in striatal neurons, thus restoring the normal dopamine levels in the pars compacta of the substantia nigra.

CONCLUSION

This study confirms that the application of warm water caloric vestibular stimulation enhances dopamine level and motor activity in rotenoneinduced PD rats when assessed using Actophotometer. Hence, in future translational research among human subjects can be recommended using caloric vestibular stimulation for enhancement of dopamine and motor activity in Parkinson's disease.

ACKNOWLEDGEMENT

We would like to express sincere thanks to the faculty of Siddha Central Research Institute, Arumbakkam, Chennai, for their support in the technical aspects of this project.

Funding Support

None.

Conflict of Interest

None.

REFERENCES

Alam, M., Schmidt, W. J. 2002. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. *Behavioural Brain Research*, 136(1):317–324.

- Cannon, J. R., Tapias, V., Na, H. M., Honick, A. S., Drolet, R. E., Greenamyre, J. T. 2009. A highly reproducible rotenone model of Parkinson's disease. *Neurobiology of Disease*, 34(2):279–290.
- Fearnley, J. M., Lees, A. J. 1991. Aging and Parkinson's disease: substantia nigra regional selectivity. *Brain*, 114(5):2283–2301.
- Gopinath, A., Archana, R., Sailesh, K. S., Mukkadan, J. K. 2015. Effect of caloric vestibular stimulation on memory. *International Journal of Pharma and Bio Sciences*, 6:453–459.
- Horii, A., Takeda, N., Mochizuki, T., Okakura-Mochizuki, K., Yamamoto, Y., Yamatodani, A. 1994. Effects of vestibular stimulation on acetylcholine release from rat hippocampus: an in vivo microdialysis study. *Journal of Neurophysiology*, 72(2):605–611.
- Narasimhan, K. K. S., Jayakumar, D., Velusamy, P., Srinivasan, A., Mohan, T., Ravi, D. B., Uthamaraman, S., Sathyamoorthy, Y. K., Rajasekaran, N. S., Periandavan, K. 2019. Morinda citrifolia and Its Active Principle Scopoletin Mitigate Protein Aggregation and Neuronal Apoptosis through Augmenting the DJ-1/Nrf2/ARE Signaling Pathway. *Oxidative Medicine and Cellular Longevity*, 2019:1– 13.
- Sailesh, K. S., Archana, R., Mukkadan, J. K. 2014a. Controlled Vestibular Stimulation: A Physiological Method of Stress Relief. *Journal of Clinical and Diagnostic Research*, 8(12):BM01–BM02.
- Sailesh, K. S., Usha, R., Padmanabha, P., Abraham, J., Mukkadan, J. K. 2014b. Can Controlled Vestibular Stimulation Delay Brain Aging? *Asian Journal of Health Sciences*, 2(1).
- Samoudi, G., Nissbrandt, H., Dutia, M. B., Bergquist, F. 2012. Noisy Galvanic Vestibular Stimulation Promotes GABA Release in the Substantia Nigra and Improves Locomotion in Hemiparkinsonian Rats. *PLoS ONE*, 7(1):e29308–e29308.
- Saravanan, K. S., Sindhu, K. M., Mohanakumar, K. P. 2005. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. *Brain Research*, 1049(2):147–155.
- Sharma, V. D., Lyons, K. E., Nazzaro, J. M., Pahwa, R. 2019. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease patients over 75 years of age. *Journal of the Neurological Sciences*, 399:57–60.

Sherer, T. B., Betarbet, R., Testa, C. M., Seo, B. B., Richardson, J. R., Kim, J. H., Miller, G. W., Yagi, T., Matsuno-Yagi, A., Greenamyre, J. T. 2003. Mechanism of Toxicity in Rotenone Models of Parkinson's Disease. *The Journal of Neuroscience*, 23(34):10756–10764.

- Suzuki, M., Kitano, H., Ito, R., Kitanishi, T., Yazawa, Y., Ogawa, T., Shiino, A., Kitajima, K. 2001. Cortical and subcortical vestibular response to caloric stimulation detected by functional magnetic resonance imaging. *Cognitive Brain Research*, 12(3):441–449.
- Tieu, K. 2011. A Guide to Neurotoxic Animal Models of Parkinson's Disease. *Cold Spring Harbor Perspectives in Medicine*, 1(1):1–20.
- von Wrangel, C., Schwabe, K., John, N., Krauss, J. K., Alam, M. 2015. The rotenone-induced rat model of Parkinson's disease: Behavioral and electrophysiological ϐindings. *Behavioural Brain Research*, 279:52–61.
- Wagner, J., Vitali, P., Palfreyman, M. G., Zraika, M., Huot, S. 1982. Simultaneous Determination of 3,4- Dihydroxyphenylalanine, 5-Hydroxytryptophan, Dopamine, 4-Hydroxy-3-Methoxyphenylalanine, Norepinephrine, 3,4-Dihydroxyphenylacetic Acid, Homovanillic Acid, Serotonin, and 5- Hydroxyindoleacetic Acid in Rat Cerebrospinal Fluid and Brain by High-Performance Liquid Chromatography with Electrochemical Detection. *Journal of Neurochemistry*, 38(5):1241–1254.
- Yabe, I., Ohta, M., Egashira, T., Sato, K., Kano, T., Hirotani, M., Kunieda, Y., Sasaki, H. 2014. Effectiveness of zonisamide in a patient with Parkinson's disease and various levodopa-induced psychotic symptoms. *Neurology and Clinical Neuroscience*, 2(6):201–203.